Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay

Julie A. Lynch, Megan P. Rothney, Raoul R. Salup, Cesar E. Ercole, Sharad C. Mathur, David A. Duchene, Joseph W. Basler, Javier Hernandez, Michael A. Liss, Michael P. Porter, Jonathan L. Wright, Michael C. Risk, Mark Garzotto, Olga Efimova, Laurie Barrett, Brygida Berse, Michael J. Kemeter, Phillip G. Febbo, Atreya Dash

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

BACKGROUND: Active surveillance (AS) has been widely implemented within Veterans Affairs' medical centers (VAMCs) as a standard of care for low-risk prostate cancer (PCa). Patient characteristics such as age, race, and Agent Orange (AO) exposure may influence advisability of AS in veterans. The 17-gene assay may improve risk stratification and management selection. OBJECTIVES: To compare management strategies for PCa at 6 VAMCs before and after introduction of the Oncotype DX Genomic Prostate Score (GPS) assay. STUDY DESIGN: We reviewed records of patients diagnosed with PCa between 2013 and 2014 to identify management patterns in an untested cohort. From 2015 to 2016, these patients received GPS testing in a prospective study. Charts from 6 months post biopsy were reviewed for both cohorts to compare management received in the untested and tested cohorts. SUBJECTS: Men who just received their diagnosis and have National Comprehensive Cancer Network (NCCN) very low-, low-, and select cases of intermediate-risk PCa. RESULTS: Patient characteristics were generally similar in the untested and tested cohorts. AS utilization was 12% higher in the tested cohort compared with the untested cohort. In men younger than 60 years, utilization of AS in tested men was 33% higher than in untested men. AS in tested men was higher across all NCCN risk groups and races, particular in low-risk men (72% vs 90% for untested vs tested, respectively). Tested veterans exposed to AO received less AS than untested veterans. Tested nonexposed veterans received 19% more AS than untested veterans. Median GPS results did not significantly differ as a factor of race or AO exposure. CONCLUSIONS: Men who receive GPS testing are more likely to utilize AS within the year post diagnosis, regardless of age, race, and NCCN risk group. Median GPS was similar across racial groups and AO exposure groups, suggesting similar biology across these groups. The GPS assay may be a useful tool to refine risk assessment of PCa and increase rates of AS among clinically and biologically low-risk patients, which is in line with guideline-based care.

Original languageEnglish (US)
Pages (from-to)S4-S10
JournalThe American journal of managed care
Volume24
Issue number1
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay'. Together they form a unique fingerprint.

  • Cite this

    Lynch, J. A., Rothney, M. P., Salup, R. R., Ercole, C. E., Mathur, S. C., Duchene, D. A., Basler, J. W., Hernandez, J., Liss, M. A., Porter, M. P., Wright, J. L., Risk, M. C., Garzotto, M., Efimova, O., Barrett, L., Berse, B., Kemeter, M. J., Febbo, P. G., & Dash, A. (2018). Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay. The American journal of managed care, 24(1), S4-S10.